

The logo for Seeking Alpha, with the text 'Seeking Alpha' in white and a gold Greek letter alpha symbol to the right, all on a dark red background.

## AVI Biopharma Q3 2005 Earnings Conference Call Transcript (AVII)

### Earnings Call Excerpt

---

#### **Third Quarter 2005 Financial Results Conference Call Transcript**

**Moderator: Denis Burger**

**November 4, 2005 8:00 a.m. Pacific Time**

**Operator:**

Welcome to the AVI BioPharma 2005 Third Quarter Financial Results conference call.

At this time all participants are in a listen-only mode.

Following management's prepared remarks, we'll hold a Q&A session. To ask question please press star followed by 1 on your touchtone phone. If anyone has difficulty hearing the conference please press star 0 for an operator assistance.

As a reminder this conference this conference is being recorded today, November 4, 2005.

I would now like to turn the conference over to Ms. Jody Cain. Please go ahead ma'am.

**Jody Cain:**

This is (Jody Cain) with Lippert/Heilshorn & Associates. Thank you for participating in today's call. Joining me from AVI BioPharma are Denis Burger, chairman and chief executive officer, Alan Timmins, president and chief operating officer and Mark Webb, chief financial officer.

This morning AVI BioPharma released financial results for the third quarter of 2005. If you have not received this new release or if you'd like to be added to the company's distribution list please call Lippert/Heilshorn in Los Angeles at 310-691-7100 and speak with Cheryl Guertin.

This call is also being broadcast live over the Internet at [www.avibio.com](http://www.avibio.com) and a replay of this call will be available on the company's Web site for the next two weeks.

Before we begin I'd like to note that comments made by management during this conference call will include forward-looking statements within the meaning of federal securities laws. These forward-looking statements involve material risks and uncertainties. For a discussion of risk factors, I encourage you to review the AVI BioPharma Annual Report on Form 10-K and subsequent reports as filed with the Securities and Exchange Commission.

Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 4, 2005. The company undertakes no obligation

to revise or update any statements to reflect events or circumstances after the date of this conference call.

With that said, I'd like to turn the call over to Denis Burger.

Denis.

**Denis Burger:**

Thank you, Jody and thank you all for joining us today. The third quarter and recent weeks have been an exceptionally productive time at AVI and we have several developments to discuss in today's call.

I will start with a brief overview of several recent events. Mark Webber will summarize our financial results and Alan Timmins will then highlight several programs in greater detail. I will conclude with a review of key programs and will then take your questions.

Thanks, Alan. As we have discussed we believe our NeuGene-based antiviral and antitoxin projects, which we call our ?rapid response therapeutics,

Copyright © 2008 CNET Networks, Inc. All Rights Reserved.